ArticleHemaSphere2025

Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial.

Alexander Fosså et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.